<DOC>
	<DOC>NCT01023945</DOC>
	<brief_summary>The primary purpose of this study is to evaluate the pharmacodynamic profile (blood glucose and urinary glucose excursion) of ASP1941 in patients with type 2 diabetes mellitus. Safety, tolerability and pharmacokinetics are also evaluated.</brief_summary>
	<brief_title>A Study of ASP1941 in Japanese Patients With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<criteria>Type 2 diabetic patients for at least 12 weeks HbA1c value between 7.0 and 10.0% at screening Fasting plasma glucose ≥ 126mg/dL and &lt; 240mg/dL at screening Body Mass Index (BMI) 20.0 45.0 kg/m2. Type 1 diabetes mellitus patients Serum creatinine &gt; upper limit of normal Proteinuria（albumin/creatinine ratio &gt; 300mg/g） Dysuria and/or urinary tract infection Significant renal, hepatic or cardiovascular diseases Severe gastrointestinal diseases</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>ASP1941</keyword>
	<keyword>Diabetes mellitus</keyword>
	<keyword>Blood glucose</keyword>
</DOC>